Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANN ARBOR, MI / ACCESSWIRE / February 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that Glass Lewis, a leading independent proxy voting and corporate governance advisory firm is recommending that shareholders vote "FOR" the proposed Share Consolidation/Reverse Stock Split as detailed in the Company's definitive proxy statement filed on January 17, 2024. Shareholders will be asked to vote on the Reverse Stock Split at Zomedica's upcoming special meeting of shareholders scheduled to be held on February 28, 2024.

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split)

ANN ARBOR, MI / ACCESSWIRE / February 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that it will be hosting a Virtual Investor Day event on Tuesday, February 13, 2024, starting at 3:00 p.m. ET. The virtual-only webcast event will feature presentations from select members of the management team.

Zomedica to Host Virtual Investor Day February 13 at 3:00 p.m. ET

Blade Air Mobility

SNDL Inc.

In stock market investments, identifying hidden gems can be the key to unlocking extraordinary wealth. It's akin to discovering a treasure trove — a gateway to unprecedented wealth and financial transformation.

3 Hidden-Gem Penny Stocks That Could Yield Life-Changing Wealth

ANN ARBOR, MI / ACCESSWIRE / January 31, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Chief Executive Officer Larry Heaton has issued an open letter to shareholders regarding the upcoming reverse split vote. The full letter is available on the Company's website at Events & Presentations | Zomedica Inc. and is published below: Dear Zomedica Shareholders, After reviewing feedback from you, our shareholders, and IR firms and reading the various message boards, I would like to make a simple request of our shareholders: Please do your own due diligence.

Open Letter to Zomedica Shareholders from your Chief Executive Officer

ANN ARBOR, MI / ACCESSWIRE / January 30, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Larry Heaton, Chief Executive Officer, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference, taking place virtually on February 1st, 2024. The Company's webcasted fireside chat will take place at 10:15am ET on Thursday, February 1, 2024.

Zomedica to Participate in the Lytham Partners 2024 Investor Select Conference

ANN ARBOR, MI / ACCESSWIRE / January 25, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Institutional Shareholder Services ("ISS"), a leading independent proxy voting and corporate governance advisory firm, recommends that Zomedica Corp. shareholders vote "FOR" the proposed Share Consolidation/Reverse Stock Split detailed in the Company's definitive proxy statement filed on January 17, 2024. The Company's upcoming Special Virtual-only Meeting of Shareholders is scheduled to be held on February 28, 2024, at 1:00 pm EST.

Leading Proxy Advisory Firm ISS Recommends Zomedica Shareholders Vote "FOR" Proposed Reverse Stock Split

ANN ARBOR, MI / ACCESSWIRE / January 17, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today provided a business update and will be hosting a conference call. Fourth Quarter Financial Highlights Revenue for the fourth quarter of 2023 is expected to be over $7 million, a new record for the Company, compared to record fourth quarter 2022 revenue of $6.2 million, primarily driven by strong performance across many product lines, highlighted by a record quarter in the Therapeutic Device segment.

Zomedica Announces Preliminary 2023 Revenue; Provides Revenue Guidance for 2024, and Rationale for Share Consolidation ("Reverse Stock Split")

Clover Health Investments

In the volatile space of penny stocks, three companies are emerging as powerhouses with breakout potential, poised for massive gains. To begin with, the first one's organic growth, the second one's data licensing prowess in liquor retail, and the third one's strategic insurance advancements are captivating the market.

3 Breakout Penny Stocks Primed for Massive Gains

ANN ARBOR, MI / ACCESSWIRE / January 10, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that it will be hosting a conference call on Wednesday, January 17, 2024 at 4:30 p.m. ET. Management will provide a business update, including preliminary 2023 revenue and cash position, as well as other operational highlights during the call.

Zomedica Corp. to Host Conference Call on January 17, 2024, at 4:30 p.m. ET to Provide a Business Update, Preliminary 2023 Revenue and Cash Position, and Discuss the Proposed Reverse Stock Split; Provides Notice of Special Virtual-Only Meeting of Sharehol

Castor Maritime Inc

NextPlat Corp

Penny stocks are presenting as attractive buys right now as the valuations of larger-cap firms continue to stretch. The price-to-earnings (P/E) ratio of the S&P 500, for example, sits at 24.59x earnings, roughly in line with its long-term average.

Budget Bets: Top 3 Penny Stocks with Potential for Explosive Growth

ANN ARBOR, MI / ACCESSWIRE / January 4, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the publication of an article validating the ability to better utilize PulseVet electro-hydraulic shock wave therapy in canine patients without sedation. The article, titled "Use of a novel shockwave trode results in better patient acceptance in awake canine patients treated for musculoskeletal disease" was published in Frontiers in Veterinary Science and written by Dr. Gina L.

Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece

ANN ARBOR, MI / ACCESSWIRE / December 18, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the commercial launch of three new assays: Canine Pancreatic Lipase (cPL), Cobalamin (B12) and Folate, for the TRUFORMA® In-Clinic Biosensor Testing Platform. "Some of the most common patients a veterinarian sees are dogs presenting non-infectious Gastrointestinal disease signs, like vomiting and diarrhea," said Larry Heaton, Zomedica's Chief Executive Officer.

Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease

ANN ARBOR, MI / ACCESSWIRE / December 6, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the presentation of new clinical data supporting new indications for shock wave therapy at the recent meeting of the American Association of Equine Practitioners (AAEP) annual meeting in San Diego, California. Principal Investigator Dr. Beau Whitaker of Brazos Valley Equine Hospital (Salado, TX) presented results from the study showing that barrel racing horses with Exercise Induced Pulmonary Hemorrhage (EIPH) could be successfully treated with PulseVet's electrohydraulic shock wave therapy.

Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners

ANN ARBOR, MI / ACCESSWIRE / November 28, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today announced that the management team will be attending Noble Capital Markets' 19th Annual Emerging Growth Equity Conference at Florida Atlantic University's Executive Education Complex in Boca Raton, Florida on December 5, 2023. Zomedica CEO Larry Heaton will be presenting a Company overview and business update at 2:30 p.m.

Zomedica to Present at Noble Capital Markets' 19th Annual Emerging Growth Equity Conference

ANN ARBOR, MI / ACCESSWIRE / November 20, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today announced that the management team will attend the 35th Annual Piper Sandler Healthcare Conference in New York City on November 28, 2023. Zomedica CEO Larry Heaton will be presenting a Company overview and business outlook at 10:30 a.m.

Zomedica to Present at the 35th Annual Piper Sandler Healthcare Conference

Zomedica Corp. (NYSE:ZOM ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Elif McDonald - Investor Relations Larry Heaton - Chief Executive Officer Peter Donato - Chief Financial Officer Conference Call Participants Jason Kolbert - Dawson James Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to Zomedica's Third Quarter 2023 Earnings Release and Business Update Call.

Zomedica Corp. (ZOM) Q3 2023 Earnings Call Transcript

ANN ARBOR, MI / ACCESSWIRE / November 13, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported consolidated financial results for the quarter ended September 30, 2023. 2023 Third Quarter Financial Highlights Revenues for the third quarter of 2023 grew 31% to $6.3 million, compared to third quarter 2022 revenues of $4.8 million, primarily driven by: Growth in the Therapeutic Devices segment, where revenues from PulseVet® and Assisi® product sales came in at $6.0 million, reflecting an increase of 28% over third quarter 2022 revenues; Growth in the Diagnostic segment, where revenues from TRUFORMA®, TRUVIEWTM and VetGuardian® product sales grew to $0.3 million, more than triple the revenues of $0.1 million reported in the same quarter in 2022.

Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies

ANN ARBOR, MI / ACCESSWIRE / November 2, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on Monday, November 13, 2023 at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its third quarter ended September 30, 2023.

Zomedica to Report Third Quarter 2023 Financial Results and Provide Business Update on November 13 at 4:30 p.m. ET

ANN ARBOR, MI / ACCESSWIRE / October 11, 2023 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that Larry Heaton, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023. Company Webcast The Company's webcast presentation will be available for viewing at 7:00am ET on Tuesday, October 17, 2023, on the Company's website at https://investors.zomedica.com/ or https://wsw.com/webcast/lytham9/zom/1900656.

Zomedica to Participate in the Lytham Partners Fall 2023 Investor Conference

ANN ARBOR, MI / ACCESSWIRE / October 5, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic devices for companion animals, today announced the acquisition of Qorvo Biotechnologies LLC (QBT), creators of the OmniaTM and TRUFORMA® point of care diagnostic platforms. Qorvo Biotechnologies, a wholly owned subsidiary of Qorvo US, Inc., focused on the development of point-of-care (POC) diagnostics solutions leveraging Qorvo's innovative Bulk Acoustic Wave (BAW) sensor technology.

Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech LLC, Accelerating Timeline to Gain Control of Manufacturing and Research & Development

Presentation on Tuesday, October 3rd at 1:00 PM PT Ann Arbor, Michigan--(Newsfile Corp. - September 27, 2023) - Zomedica Corp. (NYSE American: ZOM) (the "Company") announced today that the Company is scheduled to provide a strategic overview and its prospects for growth during the LD Micro Main Event XVI Conference from October 3-5, 2023 at the Luxe Sunset Boulevard Hotel in Bel Air, California., announced today that it will be presenting at the 16th annual Main Event on Tuesday, October 3rd at 1:00 PM PT at the Luxe Sunset Boulevard Hotel.

Zomedica, Inc. to Present at the LD Micro Main Event XVI

ANN ARBOR, MI / ACCESSWIRE / September 14, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced the commercial launch of its newest assay - endogenous ACTH (eACTH) for equine plasma - for the TRUFORMA In-Clinic Biosensor Testing Platform. Larry Heaton, Zomedica's Chief Executive Officer, commented, "For the last two years the TRUFORMA diagnostic platform has brought novel point of care diagnostic capabilities to small animal veterinarians, including Feline Optimized TSH and canine endogenous ACTH assays.

Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of First-and-only Point of Care eACTH Assay for Diagnosis and Management of Cushing's Disease in Horses

ANN ARBOR, MI / ACCESSWIRE / September 13, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary diagnostic company, today announced that, as disclosed in its Current Report on Form 8-K filed with the SEC on September 13, 2023 (the "NYSEA Form 8-K"), it has received formal notice from the NYSE American that it is not in compliance with the NYSE American's continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide because the Company's common shares have been selling for a substantial period of time at a low price per share. The Company's receipt of the notice from the NYSE American does not result in the immediate delisting of the Company's common shares.

Zomedica Provides Corporate Update

Hookipa Pharma Inc

Invivyd Inc

Moderna

Novavax

Seelos Therapeutics

Amyris Inc

Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.

7 Biotech Stocks to Sell in September Before They Crash & Burn

ANN ARBOR, MI / ACCESSWIRE / September 5, 2023 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced it has completed the acquisition of Structured Monitoring Products, Inc. (SMP), the makers of the VetGuardian™ touchless vital signs monitoring technology. "We are excited about continuing to bring this groundbreaking technology to veterinarians around the world, stated Greg Blair, VP of Business Development and Strategic Planning for Zomedica.

News for Zomedica Stock (ZOM)